HHS is reviewing all doctors' orders for monoclonal antibodies. Rep. Chip Roy wants to know why

- THE BLAZE - SEP 13, 2021 - CHRIS PANDOLFO -

Eva Marie Uzcategui/Bloomberg via Getty Images

A Republican lawmaker is demanding to know why the Biden administration appears to be limiting the ability of doctors to order early treatment medications for COVID-19 patients.

Rep. Chip Roy (R-Texas) on Monday sent a letter to Department of Health and Human Services Secretary Xavier Becerra inquiring about a recent change in HHS policy that limits orders and shipments of monoclonal antibody treatments to HHS-approved administration sites.

"As you know, antibody treatments such as bamlanivimab, bamlanivimab/etesevimab, and casirivimab/imdevimab were approved under Emergency Use Authorizations (EUA) and have been shown to be effective in treating COVID-19 patients," Roy wrote to Becerra.

"Providers across the country, including providers in Texas, have utilized these treatments, aiding in effective treatment of COVID-19 patients. Unfortunately, numerous doctors and healthcare professionals who serve COVID-19 patients are reportedly being denied or limited orders for these treatments by HHS," he wrote.

Monoclonal antibody (mAb) therapy is a treatment for COVID-19 that studies have shown is effective at reducing the risk of hospitalization and death for patients with mild to moderate illness who receive early treatment. The Food and Drug Administration has granted emergency use authorization for mAb therapies to treat mild to moderate COVID-19 in adults and children older than 12, and the treatment has been promoted across the ideological spectrum by figures like Dr. Anthony Fauci and Florida Gov. Ron DeSantis.

LEIA MAIS NO RIGINAL:

https://www.theblaze.com/news/hhs-reviewing-orders-for-monoclonal-antibodies

Para acessar o Conteúdo acima, acesse a Home Page aqui. https://www.heitordepaola.online/